- Home
- Reports and publications
- Public policies
Reports and publications - Public policies
| Public policies |  |
|
Download | |
|---|---|---|---|---|
|
|
|||
| GSK access and developing countries |
|
|||
| Cervical cancer prevention | |
|
PDF (70Kb) | |
| Clinical trials in the developing world | |
|
PDF (103Kb) | |
| IP and access to medicines in developing countries | |
|
PDF (89Kb) | |
| Technology transfer, capacity building and developing countries | |
|
PDF (174Kb) | |
|
|
|||
| GSK and research & development | |
|||
| Cloning technologies and stem cell research | |
|
PDF (77Kb) | |
| The care and ethical use of animals in research | |
|
PDF (78Kb) | |
| The role of transgenic animals in biomedical research | |
|
PDF (128Kb) | |
| Disclosure of clinical trial information | |
|
PDF (110Kb) | |
| Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines |
|
|
PDF (81Kb) | |
| The use of great apes in research |
|
|
PDF (56Kb) | |
| |
|
|
||
| GSK and intellectual property | |
|||
| Evergreening | |
|
PDF (102Kb) | |
| Compulsory licences | |
|
PDF (82Kb) | |
| Gene patenting | |
|
PDF (74Kb) | |
| Proposals for a disclosure in patent applications | |
|
PDF (91Kb) | |
| Regulatory data protection | |
|
PDF (159Kb) | |
|
|
|||
| GSK and the environment | |
|||
| Climate change | |
|
PDF (56Kb) | |
| Hazardous chemical management | |
|
PDF (68Kb) | |
| Ozone depletion and metered-dose inhalers for asthma | |
|
PDF (73Kb) | |
| Pharmaceuticals in environment | |
|
PDF (69Kb) | |
| GSK and REACH | |
|
PDF (50Kb) | |
| GSK and the convention on biological diversity | |
|
PDF (98Kb) | |
| The impact of climate change on health | |
|
PDF (75Kb) | |
| Use of ozone depleting substances in ancillary plant and equipment | |
|
PDF (56Kb) | |
| Nanomaterials | |
|
PDF (66Kb) | |
|
|
|||
| GSK and public health | |
|||
| The provision by the pharma industry of information to patients | |
|
PDF (106Kb) | |
| Counterfeiting of healthcare products | |
|
PDF (74Kb) | |
| Pharmacovigilance |
|
|
PDF (93Kb) | |
| Paediatric medicines |
|
|
PDF (137Kb) | |
| Pandemic preparedness |
|
|
PDF (3.4Mb) | |
| |
|
|
||
| GSK and competitiveness | |
|||
| Competitiveness and investment criteria | |
|
PDF (76Kb) | |
| Key aspects of a sustainable healthcare system | |
|
PDF (128Kb) | |
| |
|
|
||
| GSK pricing, reimbursement and market access | |
|||
| Pricing and reimbursement | |
|
PDF (93Kb) | |
| Health technology assessments | |
|
PDF (107Kb) | |
| Incremental innovation | |
|
PDF (77Kb) | |
|
|
|||
| GSK and other issues | |
|||
| Marketing practices | |
|
PDF (79Kb) | |
| Product donations | |
|
PDF (2.6Mb) | |
Back to top
This section contains information in several formats:
To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.
For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.